Related Experiment Video

Updated: Nov 17, 2025

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.3K

Aurora kinase inhibitors: a patent review (2014-2020)

Xue-Li Jing1, Shi-Wu Chen1

  • 1School of Pharmacy, Lanzhou University, Lanzhou, China.

Expert Opinion on Therapeutic Patents
|February 12, 2021
PubMed

Insights

Aurora kinase inhibitors show promise for cancer treatment, with ongoing research focusing on selective or multi-target drugs. Despite clinical efficacy, no Aurora kinase inhibitor is approved yet, but development continues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Aurora kinases are crucial for cell division and are overexpressed in various cancers.
  • Small-molecule inhibitors targeting Aurora kinases represent a potential cancer therapeutic strategy.

Purpose of the Study:

  • To review updated clinical trial information and patents for Aurora kinase inhibitors filed between 2014 and 2020.
  • To analyze the current development trends in Aurora kinase inhibitor research.

Main Methods:

  • Literature search using PubMed, Scopus, SciFinder, and clinicaltrials.gov.
  • Review of patents and clinical trial data for Aurora kinase inhibitors.

Main Results:

  • Aurora kinase inhibitors, including selective and pan inhibitors, demonstrate preclinical and clinical efficacy.
  • No Aurora kinase inhibitor has received FDA approval for clinical use to date.

Conclusions:

  • Despite efficacy, the lack of approved Aurora kinase inhibitors highlights challenges in clinical translation.
  • Current trends focus on highly selective or multi-target inhibitors, used as single agents or in combination therapies.
Keywords:
anticanceraurora kinaseclinical trialscombination therapyinhibitorpatent

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.1K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
79
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.2K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.1K